Botulinum Toxin A Versus B in Sialorrhea: A Prospective, Randomized, Double-Blind, Crossover Pilot Study in Patients with Amyotrophic Lateral Sclerosis or Parkinson's Disease
Identifieur interne : 002614 ( PascalFrancis/Curation ); précédent : 002613; suivant : 002615Botulinum Toxin A Versus B in Sialorrhea: A Prospective, Randomized, Double-Blind, Crossover Pilot Study in Patients with Amyotrophic Lateral Sclerosis or Parkinson's Disease
Auteurs : Arianna Guidubaldi [Italie] ; Alfonso Fasano [Italie] ; Tamara Lalongo [Italie] ; Carla Piano [Italie] ; Maurizio Pompili [Italie] ; Roberta Masciana [Italie] ; Luisa Siciliani [Italie] ; Mario Sabatelli [Italie] ; Anna Rita Bentivoglio [Italie]Source :
- Movement disorders [ 0885-3185 ] ; 2011.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Prospective, Homme.
English descriptors
- KwdEn :
Abstract
Background: Either botulinum toxins (BoNTs) A and B have been used for improving drooling in different neurological conditions. Methods: Consecutive patients affected by Amyotrophic Lateral Sclerosis (ALS) or Parkinson's Disease (PD) accompanied by severe drooling were randomized to receive botulinum neurotoxin type A (BoNT-A) or B (BoNT-B) injections into the salivary glands. Following the first treatment, when sialorrhea returned to baseline (at least three months after the first injection), subjects were re-treated with the other serotype. Ultrasound-guided injections into parotid and submandibular glands were bilaterally performed: total doses were 250 U BoNT-A (Dysport) and 2500 U BoNT-B (Neurobloc). Objective (cotton roll weight) and subjective (ad hoc clinical scales) evaluations were performed at baseline, after 1 and 4 weeks, and every 4 weeks until drooling returned to baseline. Results: Twenty-seven patients (15 ALS and 12 PD) were enrolled, fourteen completed the study. BoNT-A and BoNT-B treatments gave both subjective and objective improvements in all patients. The latency was significantly shorter after BoNT-B treatments (3.2 ± 3.7 days) compared to BoNT-A (6.6 ± 4.1 days; P = 0.002). The mean benefit duration was similar at 75 and 90 days for BoNT-A and BoNT-B, respectively (P = NS). The only toxin-related side effect was a change to saliva thickness. Conclusions: Either 250 U Dysport or 2500 U Neurobloc have similar effectiveness and safety in controlling sialorrhea. BoNT-B has a shorter latency and comparable duration. Cost analysis, considering the doses used in this study protocol favored BoNT-B treatment.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000704
Links to Exploration step
Pascal:11-0188474Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Botulinum Toxin A Versus B in Sialorrhea: A Prospective, Randomized, Double-Blind, Crossover Pilot Study in Patients with Amyotrophic Lateral Sclerosis or Parkinson's Disease</title><author><name sortKey="Guidubaldi, Arianna" sort="Guidubaldi, Arianna" uniqKey="Guidubaldi A" first="Arianna" last="Guidubaldi">Arianna Guidubaldi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Fasano, Alfonso" sort="Fasano, Alfonso" uniqKey="Fasano A" first="Alfonso" last="Fasano">Alfonso Fasano</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Lalongo, Tamara" sort="Lalongo, Tamara" uniqKey="Lalongo T" first="Tamara" last="Lalongo">Tamara Lalongo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Piano, Carla" sort="Piano, Carla" uniqKey="Piano C" first="Carla" last="Piano">Carla Piano</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Pompili, Maurizio" sort="Pompili, Maurizio" uniqKey="Pompili M" first="Maurizio" last="Pompili">Maurizio Pompili</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Istituto di Medicina Interna e Geriatria, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Masciana, Roberta" sort="Masciana, Roberta" uniqKey="Masciana R" first="Roberta" last="Masciana">Roberta Masciana</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Istituto di Medicina Interna e Geriatria, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Siciliani, Luisa" sort="Siciliani, Luisa" uniqKey="Siciliani L" first="Luisa" last="Siciliani">Luisa Siciliani</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Istituto di Medicina Interna e Geriatria, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Sabatelli, Mario" sort="Sabatelli, Mario" uniqKey="Sabatelli M" first="Mario" last="Sabatelli">Mario Sabatelli</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Rita Bentivoglio, Anna" sort="Rita Bentivoglio, Anna" uniqKey="Rita Bentivoglio A" first="Anna" last="Rita Bentivoglio">Anna Rita Bentivoglio</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0188474</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0188474 INIST</idno><idno type="RBID">Pascal:11-0188474</idno><idno type="wicri:Area/PascalFrancis/Corpus">000704</idno><idno type="wicri:Area/PascalFrancis/Curation">002614</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Botulinum Toxin A Versus B in Sialorrhea: A Prospective, Randomized, Double-Blind, Crossover Pilot Study in Patients with Amyotrophic Lateral Sclerosis or Parkinson's Disease</title><author><name sortKey="Guidubaldi, Arianna" sort="Guidubaldi, Arianna" uniqKey="Guidubaldi A" first="Arianna" last="Guidubaldi">Arianna Guidubaldi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Fasano, Alfonso" sort="Fasano, Alfonso" uniqKey="Fasano A" first="Alfonso" last="Fasano">Alfonso Fasano</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Lalongo, Tamara" sort="Lalongo, Tamara" uniqKey="Lalongo T" first="Tamara" last="Lalongo">Tamara Lalongo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Piano, Carla" sort="Piano, Carla" uniqKey="Piano C" first="Carla" last="Piano">Carla Piano</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Pompili, Maurizio" sort="Pompili, Maurizio" uniqKey="Pompili M" first="Maurizio" last="Pompili">Maurizio Pompili</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Istituto di Medicina Interna e Geriatria, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Masciana, Roberta" sort="Masciana, Roberta" uniqKey="Masciana R" first="Roberta" last="Masciana">Roberta Masciana</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Istituto di Medicina Interna e Geriatria, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Siciliani, Luisa" sort="Siciliani, Luisa" uniqKey="Siciliani L" first="Luisa" last="Siciliani">Luisa Siciliani</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Istituto di Medicina Interna e Geriatria, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Sabatelli, Mario" sort="Sabatelli, Mario" uniqKey="Sabatelli M" first="Mario" last="Sabatelli">Mario Sabatelli</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Rita Bentivoglio, Anna" sort="Rita Bentivoglio, Anna" uniqKey="Rita Bentivoglio A" first="Anna" last="Rita Bentivoglio">Anna Rita Bentivoglio</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amyotrophic lateral sclerosis</term><term>Bontoxilysin</term><term>Comparative study</term><term>Double blind study</term><term>Guidance</term><term>Human</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Prospective</term><term>Sialorrhea</term><term>Ultrasound</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Sclérose latérale amyotrophique</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Bontoxilysin</term><term>Etude comparative</term><term>Sialorrhée</term><term>Prospective</term><term>Etude double insu</term><term>Homme</term><term>Ultrason</term><term>Guidage</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Prospective</term><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Either botulinum toxins (BoNTs) A and B have been used for improving drooling in different neurological conditions. Methods: Consecutive patients affected by Amyotrophic Lateral Sclerosis (ALS) or Parkinson's Disease (PD) accompanied by severe drooling were randomized to receive botulinum neurotoxin type A (BoNT-A) or B (BoNT-B) injections into the salivary glands. Following the first treatment, when sialorrhea returned to baseline (at least three months after the first injection), subjects were re-treated with the other serotype. Ultrasound-guided injections into parotid and submandibular glands were bilaterally performed: total doses were 250 U BoNT-A (Dysport) and 2500 U BoNT-B (Neurobloc). Objective (cotton roll weight) and subjective (ad hoc clinical scales) evaluations were performed at baseline, after 1 and 4 weeks, and every 4 weeks until drooling returned to baseline. Results: Twenty-seven patients (15 ALS and 12 PD) were enrolled, fourteen completed the study. BoNT-A and BoNT-B treatments gave both subjective and objective improvements in all patients. The latency was significantly shorter after BoNT-B treatments (3.2 ± 3.7 days) compared to BoNT-A (6.6 ± 4.1 days; P = 0.002). The mean benefit duration was similar at 75 and 90 days for BoNT-A and BoNT-B, respectively (P = NS). The only toxin-related side effect was a change to saliva thickness. Conclusions: Either 250 U Dysport or 2500 U Neurobloc have similar effectiveness and safety in controlling sialorrhea. BoNT-B has a shorter latency and comparable duration. Cost analysis, considering the doses used in this study protocol favored BoNT-B treatment.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>26</s2></fA05><fA06><s2>2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Botulinum Toxin A Versus B in Sialorrhea: A Prospective, Randomized, Double-Blind, Crossover Pilot Study in Patients with Amyotrophic Lateral Sclerosis or Parkinson's Disease</s1></fA08><fA11 i1="01" i2="1"><s1>GUIDUBALDI (Arianna)</s1></fA11><fA11 i1="02" i2="1"><s1>FASANO (Alfonso)</s1></fA11><fA11 i1="03" i2="1"><s1>LALONGO (Tamara)</s1></fA11><fA11 i1="04" i2="1"><s1>PIANO (Carla)</s1></fA11><fA11 i1="05" i2="1"><s1>POMPILI (Maurizio)</s1></fA11><fA11 i1="06" i2="1"><s1>MASCIANA (Roberta)</s1></fA11><fA11 i1="07" i2="1"><s1>SICILIANI (Luisa)</s1></fA11><fA11 i1="08" i2="1"><s1>SABATELLI (Mario)</s1></fA11><fA11 i1="09" i2="1"><s1>RITA BENTIVOGLIO (Anna)</s1></fA11><fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></fA14><fA14 i1="02"><s1>Istituto di Medicina Interna e Geriatria, Università Cattolica del Sacro Cuore</s1><s2>Roma</s2><s3>ITA</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></fA14><fA20><s1>313-319</s1></fA20><fA21><s1>2011</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000190829090180</s5></fA43><fA44><s0>0000</s0><s1>© 2011 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>42 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>11-0188474</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Background: Either botulinum toxins (BoNTs) A and B have been used for improving drooling in different neurological conditions. Methods: Consecutive patients affected by Amyotrophic Lateral Sclerosis (ALS) or Parkinson's Disease (PD) accompanied by severe drooling were randomized to receive botulinum neurotoxin type A (BoNT-A) or B (BoNT-B) injections into the salivary glands. Following the first treatment, when sialorrhea returned to baseline (at least three months after the first injection), subjects were re-treated with the other serotype. Ultrasound-guided injections into parotid and submandibular glands were bilaterally performed: total doses were 250 U BoNT-A (Dysport) and 2500 U BoNT-B (Neurobloc). Objective (cotton roll weight) and subjective (ad hoc clinical scales) evaluations were performed at baseline, after 1 and 4 weeks, and every 4 weeks until drooling returned to baseline. Results: Twenty-seven patients (15 ALS and 12 PD) were enrolled, fourteen completed the study. BoNT-A and BoNT-B treatments gave both subjective and objective improvements in all patients. The latency was significantly shorter after BoNT-B treatments (3.2 ± 3.7 days) compared to BoNT-A (6.6 ± 4.1 days; P = 0.002). The mean benefit duration was similar at 75 and 90 days for BoNT-A and BoNT-B, respectively (P = NS). The only toxin-related side effect was a change to saliva thickness. Conclusions: Either 250 U Dysport or 2500 U Neurobloc have similar effectiveness and safety in controlling sialorrhea. BoNT-B has a shorter latency and comparable duration. Cost analysis, considering the doses used in this study protocol favored BoNT-B treatment.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17F</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Sclérose latérale amyotrophique</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Amyotrophic lateral sclerosis</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Esclerosis lateral amiotrófica</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Bontoxilysin</s0><s2>FE</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Bontoxilysin</s0><s2>FE</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Bontoxilysin</s0><s2>FE</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Etude comparative</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Comparative study</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Estudio comparativo</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Sialorrhée</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Sialorrhea</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Sialorrea</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Prospective</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Prospective</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Prospectiva</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Etude double insu</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Double blind study</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Estudio doble ciego</s0><s5>13</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Human</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0><s5>14</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Ultrason</s0><s5>15</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Ultrasound</s0><s5>15</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Ultrasonido</s0><s5>15</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Guidage</s0><s5>16</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Guidance</s0><s5>16</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Guiado</s0><s5>16</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Metalloendopeptidases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Metalloendopeptidases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Metalloendopeptidases</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Peptidases</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Peptidases</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Peptidases</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Stomatologie</s0><s5>37</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Stomatology</s0><s5>37</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Estomatología</s0><s5>37</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>38</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>38</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>38</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Pathologie de la moelle épinière</s0><s5>39</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Spinal cord disease</s0><s5>39</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Médula espinal patología</s0><s5>39</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>42</s5></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>42</s5></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>42</s5></fC07><fC07 i1="10" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>43</s5></fC07><fC07 i1="10" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>43</s5></fC07><fC07 i1="10" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>43</s5></fC07><fN21><s1>122</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002614 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002614 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:11-0188474
|texte= Botulinum Toxin A Versus B in Sialorrhea: A Prospective, Randomized, Double-Blind, Crossover Pilot Study in Patients with Amyotrophic Lateral Sclerosis or Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |